MYGN

Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

Retrieved on: 
Tuesday, February 27, 2024

Two of the three cohorts, including approximately 1,200 patients across more than 20 cancer types, will undergo MRD monitoring via Precise MRD.

Key Points: 
  • Two of the three cohorts, including approximately 1,200 patients across more than 20 cancer types, will undergo MRD monitoring via Precise MRD.
  • The goal of SCRUM-MONSTAR-SCREEN-3 is to generate high-quality, prospective, clinical evidence showing MRD testing can be broadly applied across cancer types and to patients with different disease severity or staging.
  • “First generation MRD tests have made remarkable progress monitoring disease recurrence and progression in cancer types with high tumor or variant burden.
  • “We’ve designed Precise MRD to be highly sensitive for application across all cancer types and look forward to this study demonstrating its utility in cancer care.”

Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Retrieved on: 
Wednesday, February 21, 2024

SALT LAKE CITY, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth quarter earnings conference call on Tuesday, February 27, 2024 at 4:30p.m.

Key Points: 
  • SALT LAKE CITY, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth quarter earnings conference call on Tuesday, February 27, 2024 at 4:30p.m.
  • The company’s quarterly earnings will be released the same day after the market closes.
  • During the call, Myriad management will provide a financial overview and business update of the company’s performance for the fourth quarter and full year 2023.
  • The 44th Annual Cowen Health Care Conference with a fireside chat featuring Sam Raha, chief operating officer, and Ben Wheeler, chief financial officer – operations, on March 5, 2024, at 12:50pm EST.

Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

Retrieved on: 
Thursday, February 15, 2024

SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately.

Key Points: 
  • SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately.
  • Dr. Reed brings nearly 15 years of clinical and academic experience rooted in genetics and obstetrics/gynecology to Myriad.
  • “We’re thrilled to welcome Dallas to the Myriad team.
  • She is a passionate women’s health leader and patient advocate who is committed to advancing diversity, equity and inclusion in clinical care and education,” said Melissa Gonzales, president of women’s health, Myriad Genetics.

Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

Retrieved on: 
Thursday, February 1, 2024

SALT LAKE CITY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has completed the acquisition from Intermountain Health of select assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah.

Key Points: 
  • SALT LAKE CITY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has completed the acquisition from Intermountain Health of select assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah.
  • Myriad’s Precise Tumor Test, which was also offered by IPG as TheraMap®: Solid Tumor, analyzes a patient’s tumor DNA to discover and target important variants within tumors.
  • Myriad will operate TheraMap: Solid Tumor solely as Precise Tumor moving forward.
  • Precise Liquid, which is expected to launch later this year, will provide convenient comprehensive genomic profiling results from a blood draw.

Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

Retrieved on: 
Tuesday, January 30, 2024

SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024.

Key Points: 
  • SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024.
  • Dr. Daneker brings more than 30 years of oncology and precision medicine experience deeply rooted in providing accessible and equitable oncology care for all patients.
  • He is an accomplished healthcare leader with a proven ability to spearhead and manage the development of precision medicine and clinical research programs in the oncology space,” said Paul J. Diaz, president and CEO, Myriad Genetics.
  • “We are delighted for George to join Myriad to lead our oncology commercial and clinical strategy as we continue to expand our oncology portfolio,” said Mark Verratti, Chief Commercial Officer, Myriad Genetics.

Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

Retrieved on: 
Thursday, January 18, 2024

SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has entered into a definitive agreement to acquire select assets from Intermountain Precision Genomics’ (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah where the Precise Tumor Test is currently performed.

Key Points: 
  • SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has entered into a definitive agreement to acquire select assets from Intermountain Precision Genomics’ (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah where the Precise Tumor Test is currently performed.
  • By bringing the Precise Tumor and Precise Liquid tests in house, Myriad will open up new opportunities for innovation, growth, and continued development of its oncology portfolio.
  • Upon the closing of the acquisition on February 1, 2024, Myriad expects to operate TheraMap: Solid Tumor solely as Precise Tumor.
  • The financial terms of the deal were not disclosed but are not material to either Myriad or Intermountain Healthcare.

Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO

Retrieved on: 
Tuesday, January 9, 2024

SALT LAKE CITY, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the American Society of Clinical Oncology (ASCO)—Society of Surgical Oncology (SSO) guideline for germline testing in patients with breast cancer.

Key Points: 
  • SALT LAKE CITY, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the American Society of Clinical Oncology (ASCO)—Society of Surgical Oncology (SSO) guideline for germline testing in patients with breast cancer.
  • Among the guidance includes:
    All patients with a current or previous diagnosis of invasive breast cancer ≤ 65 years should be offered BRCA1/2 testing.
  • Patients undergoing genetic testing should be given sufficient information before testing to provide informed consent.
  • “ASCO-SSO’s guideline update is an important step forward in advancing the use of genomics in clinical care for patients with breast cancer,” said Shelly Cummings, Vice President of Oncology Medical Affairs, Myriad Genetics.

Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 3, 2024

SALT LAKE CITY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 4:30pm PST/ 7:30pm EST.

Key Points: 
  • SALT LAKE CITY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 4:30pm PST/ 7:30pm EST.
  • The presentation will be available through a live webcast in the investor relations section of Myriad’s website at investor.myriad.com .
  • An archived edition of the presentation will be available later that day.

Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance

Retrieved on: 
Thursday, December 21, 2023

Leffler will succeed Myriad CFO Bryan Riggsbee who is retiring.

Key Points: 
  • Leffler will succeed Myriad CFO Bryan Riggsbee who is retiring.
  • Riggsbee will continue as a strategic advisor through March 31, 2024, to ensure a smooth transition.
  • Leffler has held numerous financial leadership positions and brings expertise in finance transformation, acquisitions and integrations, as well as risk management.
  • At its third quarter 2023 earnings call on November 6, Myriad updated its 2023 financial guidance and introduced 2024 revenue guidance.

Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care

Retrieved on: 
Wednesday, December 20, 2023

SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of the Myriad Collaborative Research Registry ™ (MCRR).

Key Points: 
  • SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of the Myriad Collaborative Research Registry ™ (MCRR).
  • The latest enhancements make the MCRR one of the largest pan-cancer registries freely available for research use and supports transparent clinical data sharing to advance the field.
  • Built on DNAnexus, a leading enterprise Precision Health platform, the MCRR provides a secure and easy-to-use interface for scientific data analysis, collaboration, and discovery.
  • Myriad is accepting research concept forms from individuals and institutions seeking to undertake research projects.